Genetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEO

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia.

Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior roles for Roche Diagnostics in Europe, North America and most recently Australia.

Since 2019, Ms Rossiter has been Managing Director of Roche Diagnostics, Australia which has annual turnover in excess of A$250 million and 210 staff. As part of this role, she oversaw Roche’s efforts to provide diagnostics tests for the SARS‑CoV‑2 virus in Australia during the recent pandemic. Prior to this, Ms Rossiter was global Lifecycle Leader for molecular point-of-care products with Roche Molecular Systems based in the US. During her time in this role, she achieved 160% year‑on‑year growth with the placement of over 3000 systems. During her time with Roche, Ms Rossiter also had direct executive responsibility for sales and marketing efforts in Canada and the United Kingdom.

“I am over the moon to be able to bring my extensive and proven commercial acumen as well as my knowledge of product development, regulatory processes and clinical value to a company such as Genetic Signatures” said Allison Rossiter incoming CEO of Genetic Signatures. “It is an incredibly exciting time for GSS and I am honoured to take on this role at such a pivotal time for the company and the employees.”

Ms Rossiter is joining Genetic Signatures at a time when the Company is about to launch its first FDA-cleared 3base^® product, the EasyScreen™ Gastrointestinal Parasite Detection Kit, into the US market. Ms Rossiter will commence her role as CEO of Genetic Signatures no later than the end of September 2024.

“We are delighted to secure an executive of Ms Rossiter’s calibre and experience as we commence our global expansion into the largest molecular diagnostics market, the United States” said Dr Nick Samaras, Chairman of the Board of Genetic Signatures. “Having spent the majority of her career with one of the world’s leading diagnostics company, including working extensively in North America, she is very well‑placed to lead our efforts in this key market. This is a very exciting time for Genetic Signatures as we transition to commercialising our products and technology onto the global stage.”

Ms Rossiter’s appointment as Chief Executive Officer will commence 30 September 2024, or an earlier date as mutually agreed. On commencement of Ms Rossiter’s appointment, Dr Neil Gunn, who has been acting as interim CEO, will continue his position as Non-Executive Director.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

 About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its EasyScreen™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.